Public comments urging the FDA’s Office of Women’s Health to ensure that women’s needs are represented across FDA and in the agency’s research, education, and public outreach.
We have made progress as a country, but there is still work to be done. Clinical trials need to broaden their subject base and do a better job of representing all affected parties for the sake of equality and the generation of more rational, insightful data. Patients and healthcare professionals need great transparency and “accurate information about the medical products available to them.”
Most of us want to be confident when we start a newly prescribed treatment that the medication we take will improve the ailment we seek to treat. We believe that our drugs have been tested and proven effective. We assume that the U.S. Food and Drug Administration (FDA) verifies that any drug that hits the market is safe…
Food and Drug Administration Safety and Innovation Act 907 Public Meeting: Progress on Enhancing the Collection, Analysis, and Availability of Demographic Subgroup Data
The NWHN advocates for the greater participation of women and other key groups in clinical trials for all drugs and devices, and particularly for products that are principally marketed and used by women.
In Washington, it can be hard to find an issue that politicians agree on across party lines. Last week, the U.S. House of Representatives passed the 21st Century Cures Act (H.R. 6) in a 344-77 vote, and now the bill heads to the Senate.
Mammography uses X-rays to take images of the breasts and identify cancer when it’s too small to be felt so it can be treated early and aggressively.